Stanford Cancer Institute

Stanford MEDICINE

Stanford Cancer Institute

Lymphoma

Version Date:
29 Oct 2018

Sezary Syndrome (Stage IV)

Failed 1 Systemic Therapy

LYMNHL0142 ❖
Phase II MK-3475 (Pembrolizumab) & Interferon Gamma 1-b +/- Immunotherapy in PreviouslyTreated MF/SS

PI: Kim
CITN

1st priority

LYMNHL0136 ❖
Phase I Duvelisib in Combo w/ Romidepsin or Bortezomib in Relapsed/ Refractory T-cell Lymphomas

PI: Kim
Memorial Sloan Kettering

2nd priority

LYMNHL0138
Phase 1/2A Cerdulatinib (PRT062070) in Relapsed/ Refractory CLL or SLL B-Cell or T-Cell NHL

PI: Kim
Portola Pharmaceuticals

3rd priority

Failed 2 Systemic Therapies

LYMNHL0146
Phase 1a/1b TTI-621 Targeting CD47 in Relapsed / Refractory Hematologic Malignancies & Solid Tumors

PI: Kim
Sponsor: Trillium Therapeutics Inc.

Failed 3 Systemic Therapies

LYMNHL0103
Phase III Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent /Recurrent Cutaneous NHL

PI: Kim
Esai Oncology Franchise

LYMNHL0145
Phase III Topical Naloxone Hydrochloride Lotion 0.5% in MF or SS Forms of Cutaneous T-Cell Lymphoma

PI: Kim
Sponsor: Elorac Inc.

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- ❖ Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu